Literature DB >> 6105517

Transferrin and transferrin receptors in carcinoma of the breast.

W P Faulk, B L Hsi, P J Stevens.   

Abstract

Breast tissues from 59 patients were immunohistologically studied for transferrin and transferrin receptors. None of the 8 normal breasts or 22 benign mastopathies, and only 1 of 7 fibroadenomas were reactive for transferrin, but 16 (72.7%) of 22 carcinomas were positive and parallel sections showed histopathologically that the rective areas were confined to tumour-cell membranes. That breast-tumour transferrin is probably receptor-bound in vivo was indicatd by its complete chemical removal in vitro and return to the same cells following reincubation with dilute solutions of transferrin. Similar bindig is found on certain normal or transformed cells and at the maternofetal interface of human placentae. It is suggested that this oncofetal receptor preferentially binds apotransferrin and may offer a novel approach to more specific therapy of certain breast cancers.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6105517     DOI: 10.1016/s0140-6736(80)90440-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  62 in total

1.  An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells.

Authors:  Patrick P Ng; Jay S Dela Cruz; David N Sorour; James M Stinebaugh; Seung-Uon Shin; Daniel S Shin; Sherie L Morrison; Manuel L Penichet
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

2.  The core control system of intracellular iron homeostasis: a mathematical model.

Authors:  J Chifman; A Kniss; P Neupane; I Williams; B Leung; Z Deng; P Mendes; V Hower; F M Torti; S A Akman; S V Torti; R Laubenbacher
Journal:  J Theor Biol       Date:  2012-01-23       Impact factor: 2.691

3.  Transferrin-mediated targeting of bacteriophage HK97 nanoparticles into tumor cells.

Authors:  Rick K Huang; Nicole F Steinmetz; Chi-Yu Fu; Marianne Manchester; John E Johnson
Journal:  Nanomedicine (Lond)       Date:  2011-01       Impact factor: 5.307

Review 4.  Ferritin for the clinician.

Authors:  Mary Ann Knovich; Jonathan A Storey; Lan G Coffman; Suzy V Torti; Frank M Torti
Journal:  Blood Rev       Date:  2008-10-02       Impact factor: 8.250

5.  The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells.

Authors:  V Ashutosh Rao; Sarah R Klein; Keli K Agama; Eriko Toyoda; Noritaka Adachi; Yves Pommier; Emily B Shacter
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 6.  A systems biology approach to iron metabolism.

Authors:  Julia Chifman; Reinhard Laubenbacher; Suzy V Torti
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

7.  Malarial parasites and tumour cells are killed by the same component of tumour necrosis serum.

Authors:  J Taverne; N Matthews; P Depledge; J H Playfair
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

8.  Distribution of ferritin, transferrin and lactoferrin in breast carcinoma tissue.

Authors:  R Rossiello; M V Carriero; G G Giordano
Journal:  J Clin Pathol       Date:  1984-01       Impact factor: 3.411

Review 9.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

10.  Transferrin-polycation-mediated introduction of DNA into human leukemic cells: stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels.

Authors:  M Cotten; F Längle-Rouault; H Kirlappos; E Wagner; K Mechtler; M Zenke; H Beug; M L Birnstiel
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.